Monte Rosa Therapeutics Inc Aktie News

Data support NEK7 as a potential novel and differentiated therapeutic approach to modulate the NLRP3 inflammasome in multiple cardiovascular and cardiometabolic diseases, including pericarditis and atherosclerosis Initial data from a Phase 1 study of MRT-8102 in healthy volunteers and elevated CVD-risk subjects on track for first half of 2026 Poster presentation on November 8 at 10:30 a.m. CST ...

Second agreement signed with Novartis to develop novel degraders for immune-mediated diseases, providing upfront payment of $120 million plus option maintenance payments, and eligibility for option exercise payments, milestones, and tiered royalties Phase 1 study of NEK7-directed MGD MRT-8102 underway, investigating a potential novel approach to treat inflammatory diseases driven by the NLRP3 i...

BOSTON, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that Markus Warmuth, M.D., Chief Executive Officer, will participate in fireside chats at the following investor conferences: Guggenheim 2nd Annual Healthcare Innovation Conference (Boston, ...

MRT-6160 inhibited disease pathology, including proteinuria, lymphadenopathy, skin lesion formation, autoantibody production, and organomegaly, in a spontaneous autoimmune disease mouse model  Data support the potential of MRT-6160 to address multiple rheumatic autoimmune and inflammatory diseases, including Sjögren's disease, systemic lupus erythematosus, and rheumatoid arthritis Poster presen...

Monte Rosa secured a second major Novartis deal, adding $120M upfront and up to $5.7B in milestones to its cash reserves. GLUE advances MRT-8102, a NEK7 molecular glue degrader, into Phase 1 trials targeting inflammatory and cardio-immunology disorders, with key data expected in H1 2026. Strong financial position with $295.5M in cash as of June 2025, supported by multiple big pharma collaborati...

Monte Rosa Therapeutics shares jumped this week after the company expanded its collaboration with Novartis. The Novartis partnership brings significant upfront cash and external QuEEN platform validation. Monte Rosa's molecular glue degraders can target previously undruggable proteins.

Novartis receives an exclusive license to an undisclosed discovery target Novartis also receives options to license two programs from Monte Rosa's  growing preclinical immunology portfolio Monte Rosa to receive an upfront payment of $120 million, plus option maintenance payments, and is eligible for option exercise payments and development, regulatory, and sales milestones, as well as tiered ro...

BOSTON, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that management will participate in the following investor conferences: Morgan Stanley 23rd Annual Global Healthcare Conference (New York, NY) – September 8, 2025.